Voriconazole (VFEND®) is a second-generation azole antifungal that inhibits 14-α-demethylase, causing reduced production of ergosterol, a critical component of the fungal the cell wall.  Voriconazole has a broader spectrum of activity than fluconazole and is often used for the treatment of invasive aspergillosis.  Voriconazole serum concentrations are difficult to predict because of its saturable metabolism, non-linear pharmacokinetics, and poor correlation to weight-based dosing.^{1 Continue reading →}